Sobhi M Gomha1,2, Hyam A Abdelhady2, Doaa Z H Hassain2, Aboubakr H Abdelmonsef3, Mohamed El-Naggar4, Mahmoud M Elaasser5, Huda K Mahmoud2. 1. Chemistry Department, Faculty of Science, Islamic University in Almadinah Almonawara, Almadinah Almonawara, 42351, Saudi Arabia. 2. Chemistry Department, Faculty of Science, University of Cairo, Giza, Egypt. 3. Chemistry Department, Faculty of Science, South Valley University, Qena, 83523, Egypt. 4. Chemistry Department, Faculty of Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates. 5. The Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, 11371, Egypt.
Abstract
INTRODUCTION: Hybrid drug design has developed as a prime method for the development of novel anticancer therapies that can theoretically solve much of the pharmacokinetic disadvantages of traditional anticancer drugs. Thus a number of studies have indicated that thiazole-thiophene hybrids and their bis derivatives have important anticancer activity. Mammalian Rab7b protein is a member of the Rab GTPase protein family that controls the trafficking from endosomes to the TGN. Alteration in the Rab7b expression is implicated in differentiation of malignant cells, causing cancer. METHODS: 1-(4-Methyl-2-(2-(1-(thiophen-2-yl) ethylidene) hydrazinyl) thiazol-5-yl) ethanone was used as building block for synthesis of novel series of 5-(1-(2-(thiazol-2-yl) hydrazono) ethyl) thiazole derivatives. The bioactivities of the synthesized compounds were evaluated with respect to their antitumor activities against MCF-7 tumor cells using MTT assay. Computer-aided docking protocol was performed to study the possible molecular interactions between the newly synthetic thiazole compounds and the active binding site of the target protein Rab7b. Moreover, the in silico prediction of adsorption, distribution, metabolism, excretion (ADME) and toxicity (T) properties of synthesized compounds were carried out using admetSAR tool. RESULTS: The results obtained showed that derivatives 9 and 11b have promising activity (IC50 = 14.6 ± 0.8 and 28.3 ± 1.5 µM, respectively) compared to Cisplatin (IC50 = 13.6 ± 0.9 µM). The molecular docking analysis reveals that the synthesized compounds are predicted to be fit into the binding site of the target Rab7b. In summary, the synthetic thiazole compounds 1-17 could be used as potent inhibitors as anticancer drugs. CONCLUSION: Promising anticancer activity of compounds 9 and 11 compared with cisplatin reference drug suggests that these ligands may contribute as lead compounds in search of new anticancer agents to combat chemo-resistance.
INTRODUCTION: Hybrid drug design has developed as a prime method for the development of novel anticancer therapies that can theoretically solve much of the pharmacokinetic disadvantages of traditional anticancer drugs. Thus a number of studies have indicated that thiazole-thiophene hybrids and their bis derivatives have important anticancer activity. Mammalian Rab7b protein is a member of the Rab GTPase protein family that controls the trafficking from endosomes to the TGN. Alteration in the Rab7b expression is implicated in differentiation of malignant cells, causing cancer. METHODS: 1-(4-Methyl-2-(2-(1-(thiophen-2-yl) ethylidene) hydrazinyl) thiazol-5-yl) ethanone was used as building block for synthesis of novel series of 5-(1-(2-(thiazol-2-yl) hydrazono) ethyl) thiazole derivatives. The bioactivities of the synthesized compounds were evaluated with respect to their antitumor activities against MCF-7 tumor cells using MTT assay. Computer-aided docking protocol was performed to study the possible molecular interactions between the newly synthetic thiazole compounds and the active binding site of the target protein Rab7b. Moreover, the in silico prediction of adsorption, distribution, metabolism, excretion (ADME) and toxicity (T) properties of synthesized compounds were carried out using admetSAR tool. RESULTS: The results obtained showed that derivatives 9 and 11b have promising activity (IC50 = 14.6 ± 0.8 and 28.3 ± 1.5 µM, respectively) compared to Cisplatin (IC50 = 13.6 ± 0.9 µM). The molecular docking analysis reveals that the synthesized compounds are predicted to be fit into the binding site of the target Rab7b. In summary, the synthetic thiazole compounds 1-17 could be used as potent inhibitors as anticancer drugs. CONCLUSION: Promising anticancer activity of compounds 9 and 11 compared with cisplatin reference drug suggests that these ligands may contribute as lead compounds in search of new anticancer agents to combat chemo-resistance.
Authors: Siwen Hu-Lieskovan; Stephen Mok; Blanca Homet Moreno; Jennifer Tsoi; Lidia Robert; Lucas Goedert; Elaine M Pinheiro; Richard C Koya; Thomas G Graeber; Begoña Comin-Anduix; Antoni Ribas Journal: Sci Transl Med Date: 2015-03-18 Impact factor: 17.956
Authors: P Franchetti; L Cappellacci; M Grifantini; A Barzi; G Nocentini; H Yang; A O'Connor; H N Jayaram; C Carrell; B M Goldstein Journal: J Med Chem Date: 1995-09-15 Impact factor: 7.446
Authors: Noel M O'Boyle; Michael Banck; Craig A James; Chris Morley; Tim Vandermeersch; Geoffrey R Hutchison Journal: J Cheminform Date: 2011-10-07 Impact factor: 5.514
Authors: Amr S Abouzied; Jehan Y Al-Humaidi; Abdulrahman S Bazaid; Husam Qanash; Naif K Binsaleh; Abdulwahab Alamri; Sheikh Muhammad Ibrahim; Sobhi M Gomha Journal: Molecules Date: 2022-09-27 Impact factor: 4.927
Authors: Abdel Haleem M Hussein; Abu-Bakr A El-Adasy; Ahmed M El-Saghier; M Olish; Aboubakr H Abdelmonsef Journal: RSC Adv Date: 2022-04-26 Impact factor: 4.036
Authors: Ahmed M El-Saghier; Mohamed El-Naggar; Abdel Haleem M Hussein; Abu-Bakr A El-Adasy; M Olish; Aboubakr H Abdelmonsef Journal: Front Chem Date: 2021-06-10 Impact factor: 5.221
Authors: Entesar A Hassan; Ihsan A Shehadi; Awatef M Elmaghraby; Hadir M Mostafa; Salem E Zayed; Aboubakr H Abdelmonsef Journal: Front Mol Biosci Date: 2022-01-17
Authors: Fowzia S Alamro; Nada S Al-Kadhi; Sobhi M Gomha; Saheed A Popoola; Muna S Khushaim; Omaima A Alhaddad; Hoda A Ahmed Journal: Materials (Basel) Date: 2022-03-21 Impact factor: 3.623